Bulletin
Investor Alert

New York Markets Open in:

Tilray Inc. Cl 2

NAS: TLRY

GO
/marketstate/country/us

Before the Bell

 --Quotes are delayed by 20 min

Jan 28, 2020, 6:16 a.m.

/zigman2/quotes/209129655/composite

$

18.48

Change

-0.08 -0.43%

Volume

Volume 1,000

Quotes are delayed by 20 min

/zigman2/quotes/209129655/composite

Previous close

$ 18.56

$ 18.56

Change

-1.19 -6.03%

Day low

Day high

$18.48

$19.27

Open

52 week low

52 week high

$15.01

$89.88

Open

Company Description

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extract...

Tilray, Inc. engages in the research, cultivation, production, and distribution of medical cannabis and cannabinoids. The Company is focused on medical cannabis research, cultivation, processing and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It also supplies cannabis products to patients in a number of countries spanning five continents through its subsidiaries in Australia, Canada and Germany and it produces medical cannabis in Canada and Europe. The company was founded on January 24, 2018 and is headquartered in Nanaimo, Canada.

Valuation

Price to Sales Ratio

135.76

Price to Book Ratio

33.25

Enterprise Value to EBITDA

-27.87

Enterprise Value to Sales

11.12

Total Debt to Enterprise Value

0.07

Efficiency

Revenue/Employee

62,689.00

Income Per Employee

-98,435.00

Receivables Turnover

4.40

Total Asset Turnover

0.12

Liquidity

Current Ratio

21.37

Quick Ratio

20.75

Cash Ratio

19.96

Profitability

Gross Margin

29.39

Operating Margin

-133.67

Pretax Margin

-167.34

Net Margin

-157.02

Return on Assets

-19.06

Return on Equity

-70.25

Return on Total Capital

-17.13

Return on Invested Capital

-21.50

Capital Structure

Total Debt to Total Equity

217.11

Total Debt to Total Capital

68.47

Total Debt to Total Assets

65.35

Long-Term Debt to Equity

216.87

Long-Term Debt to Total Capital

68.39

Officers and Executives

Name Age Officer Since Title
Mr. Brendan Kennedy 46 2018 President, Chief Executive Officer & Director
Mr. Jon Levin 50 2020
Mr. Michael Kruteck 54 2020
Dr. Joshua Eades - 2014 Chief Science Officer & Vice President
Ms. Kristina Adamski - 2019 Executive Vice President-Corporate Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
01/13/2020 Brendan Kennedy
President and CEO; Director
3,294   Disposition at $17.34 per share. 57,117
01/13/2020 Brendan Kennedy
President and CEO; Director
67,113   Disposition at $16.74 per share. 1,123,471
01/13/2020 Brendan Kennedy
President and CEO; Director
29,593   Disposition at $15.52 per share. 459,283
01/01/2020 Brendan Kennedy
President and CEO; Director
13,899   Derivative/Non-derivative trans. at $17.13 per share. 238,089
01/01/2020 Edward Wood Pastorius
Chief Revenue Officer
2,135   Derivative/Non-derivative trans. at $17.13 per share. 36,572
01/01/2020 Brendan Kennedy
President and CEO; Director
46,875   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2020 Michael Shtender-Auerbach
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
01/01/2020 Edward Wood Pastorius
Chief Revenue Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
12/12/2019 Michael Shtender-Auerbach
Director
2,130,577   Award at $0 per share. 0
12/12/2019 Michael Shtender-Auerbach
Director
833,351   Award at $0 per share. 0
12/12/2019 Michael Shtender-Auerbach
Director
476,641   Award at $0 per share. 0
12/12/2019 Edward Wood Pastorius
Chief Revenue Officer
41,015   Award at $0 per share. 0
12/12/2019 Edward Wood Pastorius
Chief Revenue Officer
49,985   Award at $0 per share. 0
12/12/2019 Edward Wood Pastorius
Chief Revenue Officer
61,729   Award at $0 per share. 0
12/11/2019 Brendan Kennedy
President and CEO; Director
100,000   Disposition at $18.3 per share. 1,830,000
12/02/2019 Michael Shtender-Auerbach
Director
900   Disposition at $19.81 per share. 17,829
12/02/2019 Michael Shtender-Auerbach
Director
7,537   Disposition at $19.05 per share. 143,579
12/02/2019 Michael Shtender-Auerbach
Director
31,875   Disposition at $19.05 per share. 607,218
12/02/2019 Michael Shtender-Auerbach
Director
18,750   Derivative/Non-derivative trans. at $7.76 per share. 145,500
12/01/2019 Maryscott Greenwood
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
12/01/2019 Rebekah Dopp
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
12/01/2019 Christine Thompson St. Clare
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
10/01/2019 Brendan Kennedy
President and CEO; Director
18,461   Derivative/Non-derivative trans. at $24.18 per share. 446,386
10/01/2019 Edward Wood Pastorius
Chief Revenue Officer
2,749   Derivative/Non-derivative trans. at $24.18 per share. 66,470
10/01/2019 Brendan Kennedy
President and CEO; Director
46,875   Derivative/Non-derivative trans. at $0 per share. 0
10/01/2019 Michael Shtender-Auerbach
Director
2,188   Derivative/Non-derivative trans. at $0 per share. 0
10/01/2019 Edward Wood Pastorius
Chief Revenue Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
09/01/2019 Maryscott Greenwood
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
09/01/2019 Rebekah Dopp
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
09/01/2019 Christine Thompson St. Clare
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
07/18/2019 Mark Castaneda
CFO, Secretary, Treasurer
78,700   Derivative/Non-derivative trans. at $43.41 per share. 3,416,367
07/18/2019 Mark Castaneda
CFO, Secretary, Treasurer
200,000   Derivative/Non-derivative trans. at $0 per share. 0
07/01/2019 Brendan Kennedy
President and CEO; Director
15,403   Derivative/Non-derivative trans. at $49.3 per share. 759,367
07/01/2019 Edward Wood Pastorius
Chief Revenue Officer
1,761   Derivative/Non-derivative trans. at $49.3 per share. 86,817
07/01/2019 Brendan Kennedy
President and CEO; Director
46,875   Derivative/Non-derivative trans. at $0 per share. 0
07/01/2019 Michael Shtender-Auerbach
Director
2,187   Derivative/Non-derivative trans. at $0 per share. 0
07/01/2019 Edward Wood Pastorius
Chief Revenue Officer
6,250   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/tlry

MarketWatch News on TLRY

  1. Marijuana companies are bad at forecasting, analyst says

    8:47 a.m. Jan. 14, 2020

    - Max A. Cherney

  2. Tilray names ex-Molson Coors executive Michael Kruteck as CFO

    8:22 a.m. Jan. 14, 2020

    - Ciara Linnane

  3. Tilray's current CFO Mark Castaneda will take on role in Strategic Business Development

    8:17 a.m. Jan. 14, 2020

    - Tomi Kilgore

  4. Tilray's new CFO Kruteck was formerly with Coors and Pharmaca

    8:16 a.m. Jan. 14, 2020

    - Tomi Kilgore

  5. Tilray names Michael Kruteck as CFO, Jon Levin as COO

    8:15 a.m. Jan. 14, 2020

    - Tomi Kilgore

  6. Aurora Cannabis now has a $1 price target from two analysts

    6:42 p.m. Jan. 10, 2020

    - Max A. Cherney

  7. Cannabis stocks led lower by Aurora and Hexo

    3:49 p.m. Jan. 6, 2020

    - Max A. Cherney

  8. Shorting cannabis stocks was a billion-dollar idea in 2019

    6:57 p.m. Jan. 3, 2020

    - Max A. Cherney

  9. Tilray to ship 2.5 tonnes of medical cannabis to Israel

    11:41 a.m. Jan. 2, 2020

    - Tomi Kilgore

  10. Tilray enters agreement with Canndoc to ship 2.5 mln tonnes of medical cannabis to Israel from Portugal

    11:29 a.m. Jan. 2, 2020

    - Tomi Kilgore

  11. Weed stocks rally on last day of a brutal year

    5:03 p.m. Dec. 31, 2019

    - Max A. Cherney

  12. Canada Turns to Cannabis 2.0: Edibles, Drinks, and Vapes

    8:05 p.m. Dec. 13, 2019

    - Connor Smith

  13. Loading more headlines...
/news/nonmarketwatch/company/us/tlry

Other News on TLRY

  1. 3 Reasons to Have Optimism in Canopy Growth Stock

    10:04 a.m. Jan. 27, 2020

    - InvestorPlace.com

  2. Key Catalysts Will Get Risky Aurora Stock Back On Track

    2:42 p.m. Jan. 24, 2020

    - InvestorPlace.com

  3. How Does CannTrust Stock Become a Buy Again?

    11:30 a.m. Jan. 24, 2020

    - 247WallSt.com

  4. Options Traders Expect Huge Moves in Tilray (TLRY) Stock

    8:56 a.m. Jan. 24, 2020

    - Zacks.com

  5. Will Focus on Pharma Lift Aphria Stock?

    7:36 a.m. Jan. 24, 2020

    - 247WallSt.com

  6. The Top 5 CBD Stocks Set for Sizable Growth in 2020

    9:56 a.m. Jan. 23, 2020

    - Baystreet.ca

  7. Cannabis ETF Isn't High Yet, But It's Rebounding

    6:51 a.m. Jan. 23, 2020

    - Benzinga.com

  8. Relatively Weak Aurora Stock Could Be a Multibagger in 2020

    6:45 a.m. Jan. 23, 2020

    - InvestorPlace.com

  9. Why 2020 May Be the Year for Organigram Stock

    11:42 a.m. Jan. 22, 2020

    - 247WallSt.com

  10. Weekly Cannabis Report: Earnings Season Started With A Bang

    1:34 p.m. Jan. 21, 2020

    - Seeking Alpha

  11. Congressman Backs Ballot to Legalize Psychedelic Mushrooms

    9:10 a.m. Jan. 21, 2020

    - Baystreet.ca

  12. Is It Finally Time to Buy Aurora Cannabis Stock?

    6:00 a.m. Jan. 20, 2020

    - InvestorPlace.com

  13. Netflix And Dow Heavyweights Into The Earnings Confessional

    8:23 a.m. Jan. 18, 2020

    - Seeking Alpha

  14. Here’s How Aphria Stock Could Double in 2020

    8:16 a.m. Jan. 17, 2020

    - InvestorPlace.com

  15. This Surge in Tilray Stock May Not Be a One-off Event

    6:40 a.m. Jan. 17, 2020

    - InvestorPlace.com

  16. How To Play The Canadian Cannabis Industry In 2020

    9:28 a.m. Jan. 16, 2020

    - Seeking Alpha

  17. Can Tilray Stock Make a Comeback?

    7:52 a.m. Jan. 16, 2020

    - 247WallSt.com

  18. Why 2020 Could Be an Even Uglier One for Aurora Stock

    2:48 p.m. Jan. 13, 2020

    - InvestorPlace.com

  19. Loading more headlines...

At a Glance

Tilray, Inc.

1100 Maughan Road

Nanaimo, British Columbia V9X IJ2

Phone

1 8448457291

Industry

Farming

Sector

Agriculture

Fiscal Year-end

12/2019

Revenue

$43.13M

Net Income

$-67.72M

2018 Sales Growth

110.0%

Employees

688.00

/news/pressrelease/company/us/tlry

Press Releases on TLRY

  1. Why Nanoemulsion Is The Hottest New Trend For Billion Dollar CBD Industry

    8:45 a.m. Jan. 24, 2020

    - Financial News Media

  2. The Top 5 CBD Stocks Set for Sizable Growth in 2020

    9:58 a.m. Jan. 23, 2020

    - Baystreet.ca

  3. Cannabis Company Tilray Appoints New Senior Executives

    10:13 a.m. Jan. 14, 2020

    - Baystreet.ca

  4. Tilray® Expands Global Leadership Team with New COO and CFO

    8:00 a.m. Jan. 14, 2020

    - BusinessWire - BZX

  5. Loading more headlines...
Link to MarketWatch's Slice.